Activation of M(1) and M(4) muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia

por Foster, Daniel J, Choi, Derrick L, Conn, P Jeffrey, Rook, Jerri M
Publicado 2014

Mutual activation of glutamatergic mGlu(4) and muscarinic M(4) receptors reverses schizophrenia-related changes in rodents

por Cieślik, Paulina, Woźniak, Monika, Rook, Jerri M., Tantawy, Mohammed N., Conn, P. Jeffrey, Acher, Francine, Tokarski, Krzysztof, Kusek, Magdalena, Pilc, Andrzej, Wierońska, Joanna M.
Publicado 2018

A GRM7 mutation associated with developmental delay reduces mGlu(7) expression and produces neurological phenotypes

por Fisher, Nicole M., AlHashim, Aqeela, Buch, Aditi B., Badivuku, Hana, Samman, Manar M., Weiss, Kelly M., Cestero, Gabriela I., Does, Mark D., Rook, Jerri M., Lindsley, Craig W., Conn, P. Jeffrey, Gogliotti, Rocco G., Niswender, Colleen M.
Publicado 2021

Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Sel...

por Felts, Andrew S., Rodriguez, Alice L., Blobaum, Anna L., Morrison, Ryan D., Bates, Brittney S., Thompson Gray, Analisa, Rook, Jerri M., Tantawy, Mohammed N., Byers, Frank W., Chang, Sichen, Venable, Daryl F., Luscombe, Vincent B., Tamagnan, Gilles D., Niswender, Colleen M., Daniels, J. Scott, Jones, Carrie K., Conn, P. Jeffrey, Lindsley, Craig W., Emmitte, Kyle A.
Publicado 2017